CLOs on the Move

ElectroCore

www.electrocoremedical.com

 
electroCore is, a US based electroceutical healthcare company, which is developing a range of non-invasive Vagus Nerve Stimulation (nVNS) patient administered therapies for the treatment of multiple conditions in neurology, psychiatry, gastroenterology and other fields. Initial focus is on primary headache (migraine and cluster headache), with trials continuing in epilepsy, gastric motility disorders, depression and anxiety. electroCore, which was founded in 2005, has more than 30 employees and full time consultants with offices in the US (head office), Germany (German and European head office), UK, Italy, Australia, and Canada.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Bienvenidos Foster Family Acgy

Bienvenidos Foster Family Acgy is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in West Covina, CA. To find more information about Bienvenidos Foster Family Acgy, please visit www.bienvenidos.org

Honor

Honor provides personalized home care for people who want to continue to live in the homes they love—safely and happily—as they age.

Biomed Pharmaceuticals

Biomed Pharmaceuticals is a Sharon Hill, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Menlo Therapeutics

We are a late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with various conditions. We believe that serlopitant, a highly selective small molecule inhibitor of the neurokinin 1 receptor, or NK1R, given as a once daily, oral tablet, has the potential to significantly alleviate pruritus associated with various conditions.

Kedalion Therapeutics

Kedalion Therapeutics is a clinical-stage, venture-funded ophthalmic drug company based in Menlo Park, CA. Kedalions AcuStream technology delivers topical drugs to the eye in a precise and accurate manner that enables comparable efficacy with an 80% reduction in dose compared to standard drops, and a significantly improved side effect profile along with patient comfort and convenience following self-administration.